LAWRENCEVILLE, NJ, March 15, 2023 (GLOBE NEWSWIRE) — IYESInc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that an abstract related to the Company’s DNA-based immunotherapy has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 14-19 in Orange County Convention Center in Orlando, FL and approx. The immunotherapy, IMNN-001 (formerly GEN-1), is currently in Phase 2 development for the localized treatment of advanced ovarian cancer.
The abstract is titled “Efficacy of GEN-1, an interleukin-12 immune gene therapy, at different dose frequencies.” The presentation details are as follows:
| Session Category: | Clinical Research Excludes Trials |
| Session Title: | Immunomodulatory Agents and Interventions |
| Session Date and Time: | Tuesday, April 18, 2023 (9:00 AM – 12:30 PM) |
| Location: | Poster Section 40 |
| Poster Board Number: | 26 |
| Published Abstract Number | 4440 |
| Performing: | Jean Boyer, Ph.D., Vice President of Preclinical Research, IMUNON |
The AACR abstracts were published yesterday afternoon and are now available on the AACR website at www.aacr.org.
About DRINK
IMUNON is a fully integrated clinical-stage biotechnology company dedicated to advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses to broad range of human diseases, constituting a differentiating approach from traditional therapies.
IMUNON has two technology platforms: the TheraPlas modality for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and the PLACCINE modality for the development of nucleic acid vaccines for infectious diseases and cancer. The company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by teaching the body to produce safe and stable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the site of the tumor. Additionally, the company is conducting preclinical proof-of-concept studies on a nucleic acid vaccine candidate targeting the SARS-CoV-2 virus to validate its PLACCINE platform. IMUNON’s platform technologies are based on the delivery of nucleic acids with new synthetic delivery systems that are independent of viral vectors or devices. IMUNON will continue to leverage these platforms and advance the technological frontier of nucleic acid-based products to better serve patients with difficult-to-treat conditions. For more information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IYES Readers are advised that the forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such statements have Forward-looking statements involve risks and uncertainties including, without limitation. , unexpected changes in the course of research and development activities and in clinical trials; the uncertainties and difficulties in analyzing interim clinical data; the significant cost, time and risk of failure in conducting clinical trials; the need for IYES to review its future development plans; possible acquisition or license of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IYESthe periodic reports and prospectus filed with the Securities and Exchange Commission. IYES assumes no obligation to update or supplement forward-looking statements that become untrue as a result of subsequent events, new information or otherwise.
Please contacts:
DRINK
Jeffrey W. Church
Executive Vice President, CFO
and Corporate Secretary
609-482-2455
jchurch@imunon.com
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
gogolodetz@lhai.com
##
